The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
ApexOnco Front Page
Recent articles
The company will license EGFR and cMet inhibitors from Celyn.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
The group will start a pivotal trial of samuraciclib following promising second-line results.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Global phase 2 data in TNBC look similar to earlier results in China.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
